Targeting the inflammasome in Parkinson’s disease

Published on October 12, 2022

Parkinson’s disease is like a marathon where the runner, neuroinflammation, plays a crucial role. Imagine a team of proteins as runners in this race, with α-synuclein and Parkin being key players. These proteins activate the NLRP3 inflammasome, which sparks the immune response. Scientists are studying this relationship to understand how inhibiting the NLRP3 pathway could be a game-changer in PD treatment. Potential inhibitors of the inflammasome show promise as novel therapies. As researchers delve deeper, they’re also exploring different models to test and develop these treatments in the lab and in live subjects. You can learn more about their findings and the potential future of Parkinson’s therapeutics by exploring the research!

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases in which neuroinflammation plays pivotal roles. An important mechanism of neuroinflammation is the NLRP3 inflammasome activation that has been implicated in PD pathogenesis. In this perspective, we will discuss the relationship of some key PD-associated proteins including α-synuclein and Parkin and their contribution to inflammasome activation. We will also review promising inhibitors of NLRP3 inflammasome pathway that have potential as novel PD therapeutics. Finally, we will provide a summary of current and potential in vitro and in vivo models that are available for therapeutic discovery and development.

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>